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A B S T R A C TObjectives: The purpose of this study was to compare the effects of
ticagrelor versus clopidogrel on health-related quality of life in the
PLATelet inhibition and patient Outcomes (PLATO) trial. Background:
The PLATO trial showed that ticagrelor was superior to clopidogrel for
the prevention of cardiovascular death, myocardial infarction, or
stroke in a broad population of patients with acute coronary syn-
dromes. Methods: HRQOL in the PLATO study was measured at
hospital discharge, 6-month visit, and end of treatment (anticipated
at 12 months) by using the EuroQol five-dimensional (EQ-5D) ques-
tionnaire. All patients who had an EQ-5D questionnaire assessment at
discharge from the index hospitalization (n ¼ 15,212) were included in
the study. Patients who died prior to the end-of-treatment visit were
assigned an EQ-5D questionnaire value of 0. Results: The EQ-5D
questionnaire value at discharge among 7631 patients assigned to
ticagrelor was 0.847 and among 7581 patients assigned to clopidogrelsee front matter Copyright & 2013, International
r Inc.
.1016/j.jval.2013.01.013
levin@liu.se.
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g SE-581 83, Sweden.was 0.846 (P ¼ 0.71). At 12 months, the mean EQ-5D questionnaire
value was 0.840 for ticagrelor and 0.832 for clopidogrel (P ¼ 0.046).
Excluding patients who died resulted in mean EQ-5D questionnaire
values of 0.864 among ticagrelor patients and 0.863 among clopidogrel
patients (P ¼ 0.69). Conclusions: In patients hospitalized with acute
coronary syndromes with or without ST-segment elevation, treatment
with ticagrelor was associated with a lower mortality but otherwise
no difference in quality of life relative to treatment with clopidogrel.
The improved survival and reduction in cardiovascular events with
ticagrelor are therefore obtained with no loss in quality of life.
Keywords: acute coronary syndrome, clopidogrel, quality of life,
ticagrelor.
Copyright & 2013, International Society for Pharmacoeconomics and
Outcomes Research (ISPOR). Published by Elsevier Inc.Introduction
Dual therapy with aspirin and clopidogrel is a standard treat-
ment in patients with acute coronary syndromes (ACS) [1].
Ticagrelor is an oral nonthienopyridine platelet P2Y12 receptor
inhibitor with a reversible and direct action on the receptor that
provides faster, greater, and more consistent platelet inhibition
than clopidogrel [2–4]. The PLATelet inhibition and patient Out-
comes (PLATO) trial showed that ticagrelor was superior to
clopidogrel for the prevention of cardiovascular death, myocar-
dial infarction, or stroke with no significant increase in total
major bleeding but associated with a significant increase in
non–coronary artery bypass grafting-related spontaneous major
bleeding and episodes of dyspnea in a broad population of
patients with ACS [5].
The effect of ticagrelor on health-related quality of life
(HRQOL) is unknown. The purpose of our study was to compare
the effects of ticagrelor versus clopidogrel on HRQOL, a prespe-
cified secondary objective of the PLATO Health Economic
Substudy.Methods
The PLATO trial was an international, prospective, randomized,
double-blind, double-dummy, event-driven study of patients
hospitalized with an ACS, with or without ST-segment elevation.
Details of the study design, population, and outcomes have been
published previously [5,6].
PLATO Trial Population
In the study 18,624 patients from 862 centers in 43 countries were
enrolled from October 2006 through July 2008. Patients were
randomly assigned to treatment with either ticagrelor or clopi-
dogrel within 24 hours of onset of the most recent cardiac
ischemic symptoms and before percutaneous coronary interven-
tion. Ticagrelor-assigned patients received a 180-mg loading dose
followed by a maintenance dose of 90 mg twice daily.
Clopidogrel-treated patients who had not already received a
loading dose of open-label clopidogrel, or taken clopidogrel or
ticlopidine for 5 or more days before randomization, received aSociety for Pharmacoeconomics and Outcomes Research (ISPOR).
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VA L U E I N H E A LT H 1 6 ( 2 0 1 3 ) 5 7 4 – 5 8 0 575loading dose of 300 mg, followed by a maintenance dose of 75 mg
once daily. The remaining patients received the 75-mg daily
maintenance dose of clopidogrel as their first dose.
HRQOL Study
HRQOL in the PLATO study was measured by using the EuroQol
five-dimensional (EQ-5D) questionnaire descriptive system [7].
The EQ-5D questionnaire descriptive system is a self-
administered instrument consisting of five questions, each rep-
resenting one dimension [8]. The five dimensions are mobility,
self-care, usual activities, pain and discomfort, and anxiety and
depression. For each dimension responders are asked to report
their status on a three-level ordinal scale: whether they experi-
ence no problems (level 1), some problems (level 2), or severe
problems (level 3). The 243 different health states attainable from
the EQ-5D questionnaire profile can each be assigned an EQ-5D
questionnaire single index where 1 represents the HRQOL attrib-
utable to perfect health and 0 represents the HRQOL correspond-
ing to death. Utility levels below zero can occur, indicating a
health state worse than death. The single index scores of the 243
states are based on the UK time trade-off tariff, which is based on
a general population study [9], in which responders were asked to
value EQ-5D questionnaire states in terms of trade-off utilities.
The PLATO trial enrolled patients from 43 countries; however, a
majority of them were European. We therefore adopted the UK
valuations of the health states for our analysis because they are
the most robust and representative [10]. The EQ-Visual analogue
scale, which is a part of the standard self-report EQ-5D ques-
tionnaire, was not included in the study. The EQ-5D question-
naire descriptive system has been extensively used within the
cardiovascular field to assess patient utility in trials of new
treatments and has demonstrated both high validity and reli-
ability [11].
Patients who survived until discharge from index hospital-
ization and who were living in countries with access to official
language versions of the EQ-5D questionnaire were eligible for
enrollment in the PLATO HRQOL substudy (Fig. 1). The excluded
countries were India, Philippines, Korea, Georgia, and Ukraine.
Patients were administered the EQ-5D questionnaire at discharge
from the index hospitalization, at the 6-month visit, and at the
end-of-treatment (EOT) visit, which was anticipated to be at 12
months.
Statistical Analyses
As previously described, the PLATO trial was an event-driven
study. The primary efficacy end point was death from vascular
causes, myocardial infarction, or stroke. As part of the trial,
outpatient visits were scheduled at 1, 3, 6, 9, and 12 months, with
a safety follow-up visit 1 month after the EOT. The randomized
treatment was scheduled to continue for 12 months, but patients
left the study at their 6- or 9-month visit if the targeted number
of 1780 primary end-point events had occurred by that time.
Primary Analysis
The primary end point for the HRQOL substudy was the EQ-5D
questionnaire single index utility score at 12 months after enroll-
ment. For patients who had EOT assessments at 6 or 9 months as
a result of the trial reaching the requisite number of end points,
the EQ-5D questionnaire value at the EOT assessment was
assumed to be equivalent to that at the 12-month assessment.
For patients with early EOT assessments for reasons other than
completion of the trial, or with EQ-5D questionnaire assessment
only at discharge from the index hospitalization, the last available
EQ-5D questionnaire assessment was applied on the basis of the
last value carried forward (LVCF) principle [12]. Patients who diedprior to the EOT visit were assigned an end-point value of 0. And
finally, patients who rated their health state worse than death
(negative EQ-5D questionnaire) were reassigned a value of 0.
The mean end-point EQ-5D questionnaire single index for
patients assigned to ticagrelor and clopidogrel was compared by
using a Student’s t test. Treatment comparisons were based on
intention-to-treat. The result was confirmed by using a non-
parametric bootstrap analysis with 10,000 bootstrap replicates.
A multiple linear regression model was used to study the
association between treatment, demographic and clinical factors,
and the end-point EQ-5D questionnaire single index. Variables
included in the model were treatment (ticagrelor vs. clopidogrel),
age (divided into three classes, r49 years, 50–74 years [reference
class], andZ75 years), sex, and body mass index (divided into
three classes, o25 kg/m2 [normal], 25–o30 kg/m2 [overweight,
reference class], and Z30 kg/m2 [obese]). In addition, cardiovas-
cular risk factors (including smoking status, hypertension, dysli-
pidemia, and diabetes), prior events (including prior myocardial
infarction, percutaneous coronary intervention, coronary artery
bypass grafting, congestive heart failure, stroke, peripheral arte-
rial disease, renal disease, dyspnea, chronic obstructive pulmo-
nary disease, and asthma), and presenting diagnosis were
included as covariates in the model.
Sensitivity Analyses
Six sensitivity analyses were conducted to examine the impact of
varying the assumptions made in the primary analyses on treat-
ment differences in HRQOL.
In the first sensitivity analysis, we examined treatment differ-
ences in 6-month EQ-5D questionnaire assessments in all
patients included in the primary analysis population. In the
second sensitivity analysis, instead of reassigning patients with
health states worse than death an EQ-5D questionnaire single
index value of 0, we retained the original negative values in the
analysis. Patients with EQ-5D questionnaire assessments only at
discharge from the index hospitalization or with early EOT
assessments for unknown reasons could be considered lost to
follow-up. In the third sensitivity analysis, patients with EQ-5D
questionnaire assessment only at discharge from the index
hospitalization or with early EOT assessments were excluded
from the analysis. In the fourth sensitivity analysis, we excluded
patients who died between hospital discharge and the EOT visit.
In the fifth sensitivity analysis, we restricted the patient popula-
tion to only those patients who had a 12-month EQ-5D ques-
tionnaire assessment; that is, patients who had an EOT EQ-5D
questionnaire assessment prior to 12 months or who died prior to
EOTwere excluded.
Patients who died during the index hospitalization did not
have an opportunity to participate in the PLATO HRQOL study. For
the sixth and final sensitivity analysis, we generated a maximal
data set, which included patients who died during the index
hospitalization (assigned an EQ-5D questionnaire value of 0) as
well as all patients with any EQ-5D questionnaire assessment. As
with the primary analysis, the LVCF methodology was used for
patients with the final EQ-5D questionnaire assessment prior to
the 12-month time period.
All tests of statistical significance were two-tailed, and a
probability value of 0.05 was considered to be statistically
significant. Computations for statistical analyses were done by
using the statistical software SAS, version 9.1.3.Results
Among 18,624 patients enrolled in the PLATO trial, 1,461 (8%)
were enrolled in countries in which no official language version
Fig. 1 – Flowchart showing the number of patients enrolled in the PLATO study and in the HRQOL substudy with the last
EQ-5D questionnaire assessments at various time points. EQ-5D, EuroQol five-dimensional; HRQOL, health-related quality
of life; PLATO, PLATelet inhibition and patient Outcomes.
VA L U E I N H E A LT H 1 6 ( 2 0 1 3 ) 5 7 4 – 5 8 0576of the EQ-5D questionnaire was available and 317 (2%) did not
survive to discharge from the index hospitalization (Fig. 1).
Among the remaining 16,846 patients eligible for enrollment in
the HRQOL study, 15,212 (90%) patients completed an EQ-5D
questionnaire assessment at discharge. There were no significant
differences in baseline characteristics among patients enrolled in
the HRQOL study and the overall PLATO trial or across treatment
groups among patients enrolled in the HRQOL study (Table 1).
The number of patients with the last EQ-5D questionnaire
assessments at various time points is presented in Figure 1. The
EQ-5D questionnaire value at discharge among 7631 patients
assigned to ticagrelor was 0.847 and among 7581 patients
assigned to clopidogrel was 0.846 (mean difference ¼ 0.0014, P
¼ 0.71). In 84.0% of the ticagrelor patients and 84.2% of the
clopidogrel patients, the last EQ-5D questionnaire assessment
occurred either at 12 months or at 6 or 9 months as a result of the
completion of the trial. In patients with complete EQ-5D ques-
tionnaire assessments at discharge and at 6 and 12 months,
improvements in the single index occur mainly during the first 6
months (mean increase ¼ 0.0142), while further changes over the
last 6 months were minimal (mean increase ¼ 0.0046).
Approximately 3% in each treatment arm had early EOT
assessments for other reasons, and 11% in the ticagrelor arm
and 10% in the clopidogrel arm had their last EQ-5D question-
naire assessment at discharge from the index hospitalization.
Baseline characteristics of patients with early EOT or discharge
EQ-5D questionnaire assessments did not differ significantly
from those with complete follow-up. In 2.8% of the ticagrelorpatients and 3.6% of the clopidogrel patients, the end point was
assigned the value 0 because of a death. Patients who died had on
average 0.15 lower EQ-5D questionnaire value at discharge
compared with patients who survived until the EOT visit
(P o 0.0001).
The mean difference between 12-month EQ-5D questionnaire
single index among ticagrelor and clopidogrel patients was 0.008,
statistically significant with a 95% confidence interval for the
difference of (0.00016, 0.016). These results were confirmed in a
nonparametric bootstrap analysis: P ¼ 0.047, 95% confidence
interval for the difference (0.00014, 0.016).
Factors associated with the 12-month quality of life are
presented in Table 2. Increasing age and female sex were
independently associated with lower HRQOL values. In general,
cardiovascular risk factors as well as prior clinical events were
associated with lower quality of life.
Response to the five dimensions of the EQ-5D questionnaire at
discharge and at the 12-month follow-up is illustrated in Figure 2.
In all dimensions, three quarters of the patients reported no
problems. Extreme problems were reported most frequently in
the usual activity dimension at discharge. There were no statisti-
cally significant differences in the separate dimensions of the EQ-
5D questionnaire between the ticagrelor and clopidogrel groups.
Sensitivity Analyses
Results from the six sensitivity analyses are reported in Table 3.
The mean difference between 6-month EQ-5D questionnaire
Table 1 – Baseline characteristics of patients in the full PLATO population and the full EQ-5D population.
Full PLATO population Full EQ-5D population
Ticagrelor Clopidogrel
N 18,624 7,631 7,581
Median age (y) 62 62 62
AgeZ75 y, n (%) 2,878 (15.5) 1,124 (14.7) 1,196 (15.8)
Female sex, n (%) 5,288 (28.4) 2,151 (28.2) 2,147 (28.3)
Median body weight (kg) 80 80 80
Race, n/total n (%)
White 17,077 (91.7) 7,047 (92.3) 7,001 (92.3)
Black 229 (1.2) 94 (1.2) 93 (1.2)
Asian 1,096 (5.9) 395 (5.2) 396 (5.2)
Other 222 (1.2) 95 (1.2) 91 (1.2)
BMI, n/total n (%)
Normal (o25) 5,153 (27.7) 2,019 (26.5) 2,023 (26.7)
Overweight (25–o30) 8,201 (44.0) 3,370 (44.2) 3,359 (44.3)
Obese (Z30) 5,178 (27.8) 2,228 (29.2) 2,180 (28.8)
Cardiovascular risk factor, n (%)
Habitual smoker 6,678 (35.9) 2,822 (37.0) 2,780 (36.7)
Hypertension 12,183 (65.4) 5,000 (65.5) 4,906 (64.7)
Dyslipidemia 8,689 (46.7) 3,730 (48.9) 3,707 (48.9)
Diabetes mellitus 4,662 (25.0) 1,829 (24.0) 1,867 (24.6)
Other medical history, n (%)
MI 3,824 (20.5) 1,498 (19.6) 1,530 (20.2)
PCI 2,492 (13.4) 1,025 (13.4) 1,019 (13.4)
CABG 1,106 (5.9) 448 (5.9) 474 (6.3)
Congestive heart failure 1,050 (5.6) 385 (5.0) 399 (5.3)
Nonhemorrhagic stroke 722 (3.9) 274 (3.6) 296 (3.9)
Peripheral arterial disease 1,144 (6.1) 481 (6.3) 479 (6.3)
Chronic renal disease 785 (4.2) 301 (3.9) 335 (4.4)
History of dyspnea 2,770 (14.9) 1,114 (14.6) 1,071 (14.1)
COPD 1,085 (5.8) 458 (6.0) 449 (5.9)
Asthma 532 (2.9) 228 (3.0) 226 (3.0)
Final diagnosis of ACS, n (%)
ST-elevation MI 7,026 (37.7) 2,962 (38.8) 2,972 (39.2)
Non–ST-elevation MI 7,955 (42.7) 3,321 (43.5) 3,275 (43.2)
Unstable angina 3,112 (16.7) 1,178 (15.4) 1,188 (15.7)
Other dx or missing data 531 (2.9) 170 (2.2) 146 (1.9)
ACS, acute coronary syndromes; BMI, body mass index; CABG, coronary artery bypass grafting; COPD, chronic obstructive pulmonary disease;
dx, diagnoses; EQ-5D, EuroQol five-dimensional; MI, myocardial infarction; PCI, percutaneous coronary intervention; PLATO, PLATelet
inhibition and patient Outcomes.
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0.0057 and was not statistically significant (P ¼ 0.15). A total of
153 patients (65 in the ticagrelor arm and 88 in the clopidogrel
arm) reported health states worse than death. Retaining these
negative EQ-5D questionnaire values in the analysis increased
the difference between treatments slightly (mean difference ¼
0.0085, P ¼ 0.041), with higher EQ-5D questionnaire value in
ticagrelor-treated patients. In the third sensitivity analysis, we
excluded patients with EQ-5D questionnaire assessment only at
discharge from the index hospitalization or those with early EOT.
In this subset of patients, quality of life was numerically higher
among ticagrelor-treated patients; however, the difference across
treatments was not statistically significant (mean difference ¼
0.0072, P ¼ 0.095).
Exclusion of deaths or restricting the analysis only to those
patients with a last completed EQ-5D questionnaire assessment
at the 12-month visit resulted in no treatment difference in
quality of life between patients treated with ticagrelor and
patients treated with clopidogrel.The sixth and last sensitivity analysis is based on the
maximal data set, which includes deaths during the index
hospitalization. Compared with the result from the primary
analysis, the quality-of-life difference between ticagrelor-
treated patients and clopidogrel-treated patients is increased
(mean difference ¼ 0.0113, P ¼ 0.010), essentially because of a
higher number of deaths in the clopidogrel group during the
index hospitalization.Discussion
In this large, contemporary cohort of patients with ACS enrolled
in the PLATO trial, treatment with ticagrelor was associated with
similar quality-of-life outcomes compared with treatment with
clopidogrel. Patients enrolled in the HRQOL substudy of the
PLATO trial (n ¼ 15,212) did not differ significantly in baseline
characteristics from the overall PLATO trial population (n ¼
18,624). The EQ-5D questionnaire single index value at 12 months
Table 2 – Independent determinants of the EQ-5D questionnaire single index at 12 months (n ¼ 15.212).
Parameter estimate P
Treatment: Ticagrelor vs. clopidogrel 0.0067 0.081
Age o0.0001
r49 y vs. REF 0.0094 0.12
50–74 y (REF) REF
Z75 y vs. REF 0.072 o0.0001
Sex Female vs. male 0.058 o0.0001
BMI 0.0082
Normal vs. REF 0.0093 0.052
Overweight (REF) REF
Obese vs. REF 0.014 0.0032
Cardiovascular risk factor o0.0001
Smoker 0.0049 0.27
Hypertension 0.024 o0.0001
Dyslipidemia 0.012 0.0040
Diabetes 0.029 o0.0001
Other medical history o0.0001
MI 0.035 o0.0001
PCI or CABG 0.0016 0.81
CHF 0.089 o0.0001
Nonhemorrhagic stroke 0.11 o0.0001
PAD 0.071 o0.0001
Chronic renal disease 0.070 o0.0001
Dyspnea 0.053 o0.0001
COPD 0.071 o0.0001
Asthma 0.0076 0.52
Final diagnosis 0.0020
ST-elevation MI vs. REF 0.00024 0.96
Non-ST-elevation MI (REF) REF
Unstable angina vs. REF 0.017 0.0025
Other dx or missing vs. REF 0.026 0.059
Note. R2 ¼ 0.105.
CABG, coronary artery bypass grafting; CHF, congestive heart failure; COPD, chronic obstructive pulmonary disease; dx, diagnoses; EQ-5D,
EuroQol five-dimensional; LVCF, last value carried forward; MI, myocardial infarction; PAD, peripheral arterial disease; PCI, percutaneous
coronary intervention; REF, reference.
As in the primary analysis, LVCF was used.
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VA L U E I N H E A LT H 1 6 ( 2 0 1 3 ) 5 7 4 – 5 8 0578was 0.840 among 7,631 ticagrelor-treated patients and 0.832
among 7,581 clopidogrel-treated patients (P ¼ 0.046). This result
was confirmed in a nonparametric bootstrap analysis.
Our primary analysis included all patients with at least one
EQ-5D questionnaire assessment. Patients who died during the
follow-up period were assigned an EQ-5D questionnaire value of
0. We conducted several sensitivity analyses, modifying some of
the key assumptions of our primary analysis: In the mostig. 2 – Percentage distribution of response to the EQ-5D questio
lopidogrel; EQ-5D, EuroQol five-dimensional; T, ticagrelor.conservative scenario, we restricted our patient population to
only those patients who were alive and had completed an EQ-5D
questionnaire assessment at 12 months. In this analysis, which
included less than half the original HRQOL study population, the
treatment difference (ticagrelor vs. clopidogrel) in quality of life
was negligible (0.003, P ¼ 0.63). While this result provides a
useful benchmark, we believe that it may be subject to substan-
tial selection bias. Approximately 36% of the patients in eachnnaire at discharge (D) and 12-month follow-up (12). C,
Table 3 – Results of the primary analysis and sensitivity analyses of the EQ-5D questionnaire single index.
Ticagrelor Clopidogrel Difference (P)
n (%) Mean n (%) Mean
Primary analysis (full EQ-5D questionnaire population) 7631 0.840 7581 0.832 0.0081 (0.046)
Sensitivity analyses
6-mo analysis (full EQ-5D questionnaire population) 7631 (100) 0.839 7581 (100) 0.833 0.0057 (0.1480)
Retaining negative values of the EQ-5D questionnaire single index 7631 (100) 0.839 7581 (100) 0.830 0.0085 (0.041)
Excluding patients with EQ-5D questionnaire assessment only
at discharge or early end of treatment
6623 (87) 0.843 6652 (88) 0.836 0.0072 (0.095)
Excluding patients who died 7417 (97) 0.864 7309 (96) 0.863 0.0014 (0.69)
Excluding patients without 12-mo assessment 3662 (48) 0.876 3629 (48) 0.879 0.0021 (0.63)
Using the maximal data sety 7772 (102) 0.824 7757 (102) 0.813 0.0113 (0.010)
EQ-5D, EuroQol five-dimensional.
Percentage of full EQ-5D questionnaire population.
yDeaths during the index hospitalization are included; hence, the increase in the number of assessments compared with the full EQ-5D
questionnaire population.
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result of the trial reaching the requisite number of end points. For
these patients, we assumed the EQ-5D questionnaire assessment at
EOT to be equivalent to the value that would have been observed if
they had been followed up for 12 months. Our finding of minimal
change in quality of life between 6 and 12 months among patients
with both assessments supports the validity of this assumption.
Our decision to use the LVCF methodology to include patients with
early EOT assessments (at 1 or 3 months) and those with an
assessment only at discharge from the index hospitalization is
perhaps controversial. The LVCF strategy is probably the most
frequently used approach for dealing with incomplete data in
clinical trials. It could potentially increase the type I error drasti-
cally when the course of the disease varies between treatment
groups [13]. According to our data, however, the course of the
disease is rather similar for the two treatment groups in all patients
who do not die, and so applying the LVCF strategy for these patients
is not likely to introduce any serious bias. In a sensitivity analysis
excluding these patients, treatment with ticagrelor continued
to be associated with better quality of life relative to clopidogrel,
although it was no longer statistically significant (P ¼ 0.095).
In our primary analysis, patients who rated their health state
worse than death (negative EQ-5D questionnaire) were reas-
signed a value of 0. The reason for censoring at the lower bound
of 0 is that otherwise we have to accept that a drug that kills
patients with health states valued worse than death could be
considered beneficial compared with a drug that does not kill
these patients. This is especially problematic because the valu-
ation is done by the general public and not the individual
patient. From an analysis point of view, the censoring is, maybe,
unimportant, because there are relatively few (147) censoring
cases, but from a philosophical point of view, it is important to
handle this problem properly.
The major driver of differences in quality of life across treat-
ments appears to be the valuation of deaths. The inclusion of
patients who died during the index hospitalization increased the
treatment difference to 0.013 in favor of ticagrelor (P ¼ 0.01). In
contrast, excluding patients who died during the follow-up
period nullified all treatment differences. Thus, there were no
indications that the higher rate of spontaneous bleeding and
more frequent side effects of dyspnea had any influence on the
overall quality of life as measured in the study. Therefore, the
gains in survival and cardiovascular events were obtained with-
out any loss in quality of life.
Although there have been several studies that have used the
EQ-5D questionnaire to assess quality of life among patients withcoronary heart disease [14–18], there are only a few that have
used it in the subset of patients with ACS. The MERLIN-TIMI 36
Randomized trial of ranolazine versus placebo in 6560 patients
with non–ST-elevation ACS reported an EQ-5D questionnaire
single index value of approximately 0.71 at baseline and 0.84 at
12 months [19]. In the PLATO study, patients were eligible for
enrollment if their symptom onset was during the previous 24
hours. In acute settings it is difficult to obtain a true baseline
when measuring the HRQOL. Consequently, our first EQ-5D
questionnaire measure, the assessment made at discharge from
the index hospitalization, cannot be considered as a true base-
line because it is reported after treatment initiation of the study
drug. However, the EQ-5D questionnaire values observed at 12
months are consistent with those reported in the MERLIN-TIMI
36 study.
Quality of life in patients after an episode of ACS is generally
high and not substantially different from a comparable control
population [20,21]. Thus, unlike some other secondary preventive
treatments such as antihypertensives, the benefits in survival
and reduction of cardiovascular events by long-term preven-
tive treatment with ticagrelor as compared with clopidogrel
came without any impediment to the quality of life in these
patients [22].
Our study has some strength and several limitations. To our
knowledge, our study is the largest reported population with
EQ-5D questionnaire measurement in cardiovascular diseases
including both randomized controlled trials and observational
studies [11]. We have also conducted a comprehensive set of
sensitivity analyses examining the impact of the assumptions
made in the primary analysis. It should be pointed out, however,
that the analysis presented here is a post hoc analysis, and so
any reported P values should be interpreted accordingly. Tradi-
tionally, the outcome of interest in HRQOL studies is the change
in quality of life. Baseline quality of life prior to treatment,
however, was not collected in the PLATO trial. As a result, we
were able to assess absolute rather than relative difference in
quality of life at 12 months. In our study, HRQOL was assessed by
using only the generic EQ-5D questionnaire instrument. While
this instrument has the advantage of being completed with
relative ease by the patients, incorporated into case report forms,
and validated in many languages, it may be less sensitive than a
disease-specific quality-of-life instrument [22,23]. Also, the EQ-5D
questionnaire single index reflects health status derived by using
an algorithm based on utility scores from a reference population.
Hence, it does not provide a truly personal valuation of health
status. The EQ-5D questionnaire descriptive system, however,
VA L U E I N H E A LT H 1 6 ( 2 0 1 3 ) 5 7 4 – 5 8 0580has been shown to be satisfactorily valid and reliable when
applied to patients with ACS [11,14].Conclusions
In patients hospitalized with ACS with or without ST-segment
elevation, treatment with ticagrelor was associated with a lower
mortality but otherwise no difference in quality of life relative to
treatment with clopidogrel. The improved survival and lower risk
of cardiovascular events with ticagrelor are therefore obtained
with no loss in quality of life.
Source of financial support: This study was supported by
AstraZeneca.
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